Xenon Pharmaceuticals Inc. (XENE) delivered a return of 72.77% over the past year. Since XENE does not currently pay dividends, the total return equals the price-only return.

A $10,000 investment in Xenon Pharmaceuticals Inc. one year ago would be worth $17,277 today, representing a gain of $7,277.

Xenon Pharmaceuticals Inc. (XENE) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For XENE, the total return equals the price-only return.

Yes, Xenon Pharmaceuticals Inc. (XENE) outperformed the S&P 500 by 51.93 percentage points over the past year. XENE delivered a total return of 72.77%, compared to the S&P 500's 20.84%. This 51.93pp alpha means investors in XENE earned more than a passive S&P 500 index fund.

Xenon Pharmaceuticals Inc. (XENE) experienced a maximum drawdown of -18.40% over the past year, declining from its peak on 2026-03-09 to its trough on 2026-06-08. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Here are Xenon Pharmaceuticals Inc. (XENE)'s long-term returns with dividends reinvested. Over 10 years, the total return is 782.2% (24.3% CAGR) — $10,000 would have grown to $88,222. Over 20 years: 429.3% total return (8.7% CAGR) — $10,000 → $52,933. Over 30 years: 429.3% total return (5.7% CAGR) — $10,000 → $52,933. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Xenon Pharmaceuticals Inc.'s best calendar year was 2018 with a total return of 119.1%. Its worst year was 2017 with a total return of -63.9%. This range shows the volatility investors should expect — the difference between the best and worst year is 183.0 percentage points.